Regulating the nervous system could be crucial in the response to lung cancer, new research suggests.  

Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system’s response to lung cancer, highlighting a previously unrecognised neuroimmune connection which could be targeted to improve responses to immunotherapy. 

In the new study, published in Cell, scientists also found that exposure to cigarette smoke further exploits this neuroimmune interaction, accelerating tumour growth in mice. 

The effectiveness of the immune response against cancer depends not just on immune cells being present, but also how they are organised within the tumour microenvironment – the surrounding network of cells and signals that can either support or suppress immune activity. 

“We’re starting to see the tumour microenvironment in all its complexity and what this means for disease progression,” said Leanne Li, Head of the Crick’s Cancer-Neuroscience Laboratory. 

“We’ve shown that nerves are not just present in cancers but actively shaping the tumour microenvironment and how cells talk to one another. This opens a new direction for cancer research, one that brings neuroscience and immunology together, and could reveal entirely new therapeutic opportunities.” 

Cigarette smoke causes lung cancer in other ways than DNA damage
 

In the study, researchers focussed on the nervous system’s early warning mechanism, specialised nerves that identify extreme thermal, physical, or chemical threats and trigger protective responses. By activating and deactivating these sensory nerves in mice, they demonstrated that their presence in the microenvironment was actively supporting tumour growth. 

 They also found that lung tumours increase the growth and activity of these nerves, triggering the release of a chemical messenger called calcitonin gene-related peptide (CGRP). 

Using cell and mouse models, scientists showed how CGRP interacted with immune cells called macrophages in the tumour microenvironment. Through this interaction, CGRP prevented the formation of clusters of immune cells called tertiary lymphoid structures, that are linked to better outcomes for people with lung cancer. 

When the researchers disrupted local sensory nerve activity, or directly blocked CGRP signalling, the formation of these immune structures was increased. This was accompanied by stronger immune responses and reduced tumour growth. 

With smoking the biggest risk factor for developing lung cancer, the team then decided to investigate whether cigarette smoke affects this neuroimmune pathway. They showed that cigarette smoke extract increases neuronal activity and accelerates tumour progression.  

This reveals a mechanism by which smoking can promote cancer progression beyond its role in causing DNA damage. 

“It’s fascinating to observe how sensitive the immune response is to changes in its local environment,” said Ya-Hsuan Ho, co-first author and Postdoctoral Fellow at the Crick. 

“We’ve shown that increased neuronal activity is enough to reorganise the immune landscape of the tumour and this changes how we think about immune evasion. It’s not just about the presence or absence of immune cells, it’s also how they respond to their surroundings.” 

“Even with the amazing progress we’ve seen in people benefitting from immunotherapy, a large proportion of lung cancers don’t respond,” added Giacomo Bregni, co-first author and Doctoral Clinical Fellow at the Crick. 

“This unique insight into tumour biology could offer a completely new angle to improve those responses. And because drugs targeting elements of this pathway already exist, it’s an especially promising route to explore further.” 

Crick research set to launch further study

 

Research by the Crick is now set to lay the groundwork for further work by the InteroCANCEption team. 

The team, led by Leanne Li and supported by Cancer Grand Challenges, was awarded £20 million ($27 million) in March 2026 to tackle research on the nervous system and cancer challenge. 

“Understanding how the brain might detect tumours and even influence how they grow is an emerging frontier in cancer research,” said Dr David Scott, Director of Cancer Grand Challenges. 

“This is why Cancer Grand Challenges is enabling team InteroCANCEption, led by Leanne Li, to explore this bi-directional tumour-nervous system connection and potentially develop innovative approaches that target the nervous system, expanding what is possible in cancer treatment.”